Detalles de la búsqueda
1.
Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer.
N Engl J Med;
381(21): 2020-2031, 2019 11 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-31562796
2.
Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden.
N Engl J Med;
378(22): 2093-2104, 2018 May 31.
Artículo
en Inglés
| MEDLINE | ID: mdl-29658845
3.
Safety of First-Line Nivolumab Plus Ipilimumab in Patients With Metastatic NSCLC: A Pooled Analysis of CheckMate 227, CheckMate 568, and CheckMate 817.
J Thorac Oncol;
18(1): 79-92, 2023 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36049658
4.
Detection of previously unidentified metastatic disease as a leading cause of screening failure in a phase III trial of zibotentan versus placebo in patients with nonmetastatic, castration resistant prostate cancer.
J Urol;
188(1): 103-9, 2012 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-22583636
5.
First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial.
J Thorac Oncol;
17(2): 289-308, 2022 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-34648948
6.
Preliminary study of the specific endothelin a receptor antagonist zibotentan in combination with docetaxel in patients with metastatic castration-resistant prostate cancer.
Prostate;
71(12): 1264-75, 2011 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-21271613
7.
Pain in castration-resistant prostate cancer with bone metastases: a qualitative study.
Health Qual Life Outcomes;
9: 88, 2011 Oct 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-21992720
8.
First-Line Nivolumab Plus Ipilimumab Versus Chemotherapy in Advanced NSCLC With 1% or Greater Tumor PD-L1 Expression: Patient-Reported Outcomes From CheckMate 227 Part 1.
J Thorac Oncol;
16(4): 665-676, 2021 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-33485960
9.
Satraplatin, an oral platinum, administered on a five-day every-five-week schedule: a pharmacokinetic and food effect study.
Clin Cancer Res;
15(11): 3866-71, 2009 Jun 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-19458055
10.
Nivolumab plus ipilimumab versus chemotherapy as first-line treatment in advanced non-small-cell lung cancer with high tumour mutational burden: patient-reported outcomes results from the randomised, open-label, phase III CheckMate 227 trial.
Eur J Cancer;
116: 137-147, 2019 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-31195357
11.
Nivolumab in Combination With Platinum-Based Doublet Chemotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer.
J Clin Oncol;
34(25): 2969-79, 2016 09 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-27354481
12.
Nivolumab Monotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer.
J Clin Oncol;
34(25): 2980-7, 2016 09 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-27354485
13.
Phase III, randomized, placebo-controlled study of docetaxel in combination with zibotentan in patients with metastatic castration-resistant prostate cancer.
J Clin Oncol;
31(14): 1740-7, 2013 May 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-23569308
14.
A phase II, randomized, multicenter study to assess the efficacy, safety, and tolerability of zibotentan (ZD4054) in combination with pemetrexed in patients with advanced non-small cell lung cancer.
Cancer Chemother Pharmacol;
67(5): 1203-8, 2011 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-21153822
15.
Differences in treatment patterns among patients with castration-resistant prostate cancer treated by oncologists versus urologists in a US managed care population.
Cancer Manag Res;
3: 233-45, 2011.
Artículo
en Inglés
| MEDLINE | ID: mdl-21792332
Resultados
1 -
15
de 15
1
Próxima >
>>